119.83
119.83 (0%)
As of Feb 14, 2025
Biontech Se [BNTX]
Source:
Company Overview
Biontech Se is a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases and other serious diseases.
| Country | Germany |
| Headquarters | mainz, germany |
| Phone Number | 49 6131-9084-0 |
| Industry | manufacturing |
| CEO | Prof. Ugur Sahin |
| Website | www.biontech.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2,751.1 |
| Operating Profit | $-1,314.3 |
| Net Income | $-665.3 |
| Net Cash | $-1,919.4 |
Profit Ratios
| Gross Margin | $3,292.4 |
| Operating Margin | -47.8 |
| Profit as % of Revenues | -494.9% |
| Profit as % of Assets | -2.9% |
| Profit as % of Stockholder Equity | -3.4% |
Management Effectiveness
| Return on Equity | -3.4% |
| Return on Assets | -3% |
| Turnover Ratio | 12.1% |
| EBITA | $-1,314.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $22,529.7 |
| Total Liabilities | $3,118.6 |
| Operating Cash Flow | $207.7 |
| Investing Cash Flow | $-2,081.2 |
| Financing Cash Flow | $-45.9 |
